Abstract Vitamin D deficiency has become a major public health problem worldwide due to its increasing prevalence and potential health risks. There is growing evidence from experimental studies to suggest that vitamin D may influence risk of cardiometabolic disease through multiple pathways, including inhibition of the release of proinflammatory cytokines; regulation of the renin-angiotensin system; and favorable effects on lipids, blood pressure, insulin secretion and action, and thrombosis. Human observational data, primarily from cross-sectional studies, have shown that low dietary vitamin D intake or vitamin D levels are inversely related to various cardiometabolic risk factors. Prospective studies have suggested the relationship between low 25(OH) D and increased risk of cardiometabolic disease, including hypertension, type 2 diabetes, and cardiovascular disease. Evidence from small randomized trials and post-hoc analyses of large clinical trials for the effect of vitamin D supplements on cardiometabolic risk factors, however, remains inconsistent. This article aims to summarize epidemiologic data on the relationship between vitamin D and major cardiometabolic disease and highlight the challenges in translating observational evidence to future intervention studies.
Introduction
Vitamin D is well-known for its essential role in calcium homeostasis and bone metabolism. However, a large body of evidence from observational and experimental studies has clearly suggested its other physiologic effects, especially those on individual or combined cardiometabolic parameters such as adiposity, blood pressure (BP), lipid and glucose metabolism, and insulin secretion [1] [2] [3] . Vitamin D can be obtained from diet, supplements, and conversion of 7-dehydrocholesterol in the skin by UVB radiation [1] . Vitamin D is hydroxylated in the liver to 25-hydroxyvitamin D (25[OH]D), the major circulating vitamin D metabolite [1] . 25(OH)D is further metabolized by 1α-hydroxylase to 1,25-dihydroxyvitamin D (1, 25 [OH] 2 D), the metabolically active form [1, 2] . Circulating 25(OH)D, which reflects most sources of vitamin D exposure and has a half-life of 2 to 3 weeks, has been widely used as a reliable surrogate of vitamin D status [1, 2] . 1,25(OH) 2 D binds to vitamin D receptors (VDRs), which can be found in more than 30 cell types, including intestinal cells, muscle cells, osteoblasts, parathyroid cells, epidermal cells, vascular endothelial cells, neurons, immune cells, and pancreatic β cells [1] . VDR acts as a transcription factor to regulate the rate of gene transcription in many cell types throughout the body.
Vitamin D status is determined by many factors, such as age, sex, race/skin pigmentation, season, geographic latitude, food and supplemental sources of vitamin D, adiposity, and genetic predisposition. A major source of vitamin D is the skin's synthesis of vitamin D3 from sunlight. Biological evidence indicates that melanin in the skin blocks the conversion of 7-dehydrocholesterol by UVB rays, thereby limiting vitamin D3 biosynthesis [4] . Observational studies have shown that African Americans have lower circulating levels of 25(OH)D and are more likely to be vitamin D deficient than those in other ethnic groups [4] [5] [6] . Low vitamin D status is also common in many Asian countries and the Middle East, indicating that culture, dress, or the geographical latitude limiting sun exposure may be important contributors [1] . In addition, aging may decrease the ability of skin to produce the necessary precursors for vitamin D synthesis [7] . Also, lack of sun exposure or consuming diets poor in vitamin D may increase the risk of vitamin D deficiency in older adults.
Due to the paucity of data and differences in assay methods, there is no consensus on the cutoff values of 25 (OH)D defining vitamin D insufficiency or deficiency. During 2001 to 2004, only 23 % of US adolescents and adults had serum 25(OH)D levels of 75 nmol/L or more (to define sufficient vitamin D) [8] . Strikingly, nearly all non-Hispanic blacks (97 %) and most Mexican Americans (90 %) had insufficient vitamin D levels (<75 nmol/L) [8] . The Institute of Medicine (IOM), which issued new recommended daily allowance of vitamin D and calcium in 2011, conducted a comprehensive and rigorous review of existing data on vitamin D in relation to osteoporosis and other nonskeletal outcomes-most studies conducted in non-Hispanic whitesand determined that a cutoff level of 50 nmol/L (20 ng/mL) of serum 25(OH)D is needed to maintain bone health for most individuals [9••, 10•] . Notably, the IOM Committee concluded that the evidence that vitamin D or calcium protects against risk of nonskeletal chronic disease outcomes, including hypertension, type 2 diabetes, and cardiovascular disease (CVD), was inconsistent, inconclusive, and did not meet criteria for establishing cause-and-effect relationships [9••, 10•] . Optimal 25(OH)D levels for cardiovascular health remain unknown due to limited data.
Cardiometabolic Risk Factors
Vitamin D deficiency has been associated with many adverse health outcomes, including several bone diseases, certain types of cancer, multiple autoimmune diseases, and the metabolic syndrome [1] [2] [3] . Vitamin D may influence risk of CVD through multiple pathways, including inhibition of the release of proinflammatory cytokines, regulation of the renin-angiotensin system (RAS), improvement in ventricular function, favorable effects on lipid and glucose metabolism, and insulin secretion and sensitivity (Fig. 1) .
For years, abdominal obesity, abnormal glucose metabolism, hypertension, and dyslipidemia (low high-density lipoprotein cholesterol and high triglycerides) have been linked as a cluster of metabolic abnormalities defined as the metabolic syndrome [11] . All components of the metabolic syndrome are associated with increased risks of major chronic diseases, including type 2 diabetes, CVD, chronic kidney disease, nonalcoholic fatty liver disease, polycystic ovary syndrome, and certain forms of cancer. The metabolic syndrome is now reaching epidemic proportion worldwide and may reflect a common underlying pathophysiology related to multiple cardiovascular and metabolic end points, collectively termed cardiometabolic disease [11] . The pathogenesis of cardiometabolic disease is a complex and multifactorial process. Cardiometabolic risk factors and their disease outcomes of hypertension, type 2 diabetes, CVD, and other comorbidities continue to be a global threat to public health.
Insulin Secretion and Sensitivity
A large body of literature has suggested that optimal vitamin D status is essential for both insulin action and secretion [3] , two fundamental features in the pathogenesis of type 2 diabetes. Vitamin D may directly affect pancreatic β-cell function via the binding of circulating 1,25(OH) 2 D to VDR in β cells [2, 12] . Also, vitamin D may indirectly affect calcium-dependent insulin secretion via regulation of calcium transport through the β cells [13, 14] . Intravenous administration of 1,25(OH) 2 D 3 was shown to increase insulin secretion and reduce blood glucose response to an intravenous glucose load in vitamin D-deficient rats [12] and rabbits [15] . The effect of vitamin D on insulin resistance may not be direct and could be mediated through its beneficial effects on adiposity. Several other mechanisms, including stimulating expression of insulin receptors, regulation of the calcium pool, and modulation of cytokine expression and activity, may also account for its beneficial effect on insulin action in peripheral tissues [1, 16] . Human data also show that low vitamin D status is associated with impaired β-cell function, insulin resistance, and impaired glucose tolerance [3, [16] [17] [18] . Recent randomized trials appeared to support the effect of vitamin D supplementation on insulin sensitivity. In a large trial of 314 adults aged 65 years and older, taking a combined vitamin D (700 IU/ d) and calcium supplement (500 mg/d) for 3 years prevented increases in fasting plasma glucose and insulin resistance (measured by homeostasis model assessment-estimated insulin resistance [HOMA-IR]) among impaired glucosetolerant participants, but not among women with normal fasting glucose [19] . In a randomized, placebo-controlled trial of 18 healthy white males, 1,25-(OH) 2 D 3 treatment (1.5 μg/d for 7 days) did not change mean glucose, insulin, or insulin sensitivity [20] . More recently, in a randomized, double-blind, placebo-controlled trial of 92 adults at high risk of diabetes, daily vitamin D3 supplementation (2,000 IU) with or without calcium (800 mg) for 16 weeks improved pancreatic β-cell function assessed by an intravenous glucose tolerance test and had a marginal effect on attenuating the rise in glycosylated hemoglobin (HbA1c) [21] . Given limited sample sizes and short duration, these clinical trials did not have adequate power. Furthermore, differences in study population, duration of diabetes, glycemic treatment, and intervention periods, coupled with the fact that different vitamin D doses and forms were used may explain the inconsistent results from these trials. The true beneficial effect of vitamin D in improving insulin sensitivity and pancreatic β-cell function in nondiabetic individuals has yet to be conclusively demonstrated without definitive evidence from long-term and well-designed controlled trials.
Adiposity
The interrelationship between vitamin D status and adiposity is complex and may be reciprocal. Some [17, [22] [23] [24] , but not all [25] [26] [27] observational studies have shown an inverse association between 25(OH)D levels and adiposity. Although the underlying mechanisms are not wellunderstood, increased storage of 25(OH)D in adipose tissue in obese individuals is a plausible explanation [23] . Also, less sun exposure due to limited mobility and/or more subcutaneous fat deposits in obese individuals may lead to reduced vitamin D synthesis in the skin [28, 29] . On the other hand, vitamin D may directly affect adiposity. Vitamin D is an important determinant of circulating parathyroid hormone (PTH) levels. PTH stimulates calcium influx into adipocytes, which enhances lipogenesis and inhibits lipolysis, leading to accumulation of fat [30] . Of note, measurement error due to self-reporting of anthropometric variables, including weight, height, and waist and hip circumferences, could have affected the results in previous cohort studies based on self-reported data. Future mechanistic and large cohort studies with longitudinal data are needed to help us understand the interrelations between vitamin D and adiposity.
Systemic Inflammation
Vitamin D has anti-inflammatory and immunomodulatory effects [31••] . Experimental data suggest that 1,25(OH) 2 D inhibits proinflammatory cytokines such as interleukin (IL)-6 and tumor necrosis factor-α, decreases C-reactive protein, upregulates production of the anti-inflammatory cytokine IL-10 [32] , and regulates expression of matrix metalloproteinase-9 [33] . VDRs are found on dendritic cells, T and B lymphocytes, and macrophages. Vitamin D has complex effects in both adaptive and innate immunity. The net effect of vitamin D in T cells is to suppress T-helper type 1 (Th1)-driven inflammatory responses while promoting a Th2 regulatory phenotype. Vitamin D promotes monocyte differentiation into macrophages and enhances their chemotactic and phagocytotic capacity as well as their bacterial 
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Hypertension
Vitamin D has potential antihypertensive effects, mainly through its effects on the RAS [35•] . Human study of the association between vitamin D and the RAS has been scant. Some cross-sectional analyses in the NHANES representative sample of the US population have reported that circulating 25 (OH)D and PTH were independently associated with BP and with the presence of hypertension or prehypertension, though directionality remains to be elucidated in prospective studies [36] . Most cross-sectional studies that failed to observe a significant relationship between 25(OH)D levels and BP or hypertension had small sample sizes and therefore limited statistical power. [37] Two large cross-sectional studies, the Amsterdam Longitudinal Aging Study and the RanchoBernardo Study, did not find an association [38, 39] . Their null findings may be attributed to a high prevalence of participants with prevalent hypertension and use of antihypertensive medication (80 %) [39] or with normal 25(OH)D levels (>30 ng/ mL) (98 %) [38] . Several prospective studies have examined the association between baseline 25(OH)D levels and incident hypertension or longitudinal change in BP [40] [41] [42] but yielded mixed results. In a prospective cohort study including 613 men and 1,198 women who did not have hypertension at baseline, those with 25(OH)D levels less than 15 ng/mL, compared with 30 ng/mL or greater, had a relative risk (RR) of incident hypertension of 2.67 (95 % CI, 1.05-6.79) after adjusting for multiple demographic and lifestyle factors [41] . In a nested case-control study (n01,500) within the prospective Nurses' Health Study II cohort [40] , after multivariable adjustment (including PTH), baseline 25(OH)D levels were associated with hypertension with an OR of 1.66 (95 % CI, 1.11-2.48) comparing the lowest to highest quartile. A population-based study among women 22 to 44 years of age found that low levels of 25(OH)D were associated with incident systolic hypertension (RR, 3.0 [95 % CI, 1.1-8.7]). However, recent findings from three longitudinal studies showed that 25(OH)D levels were not associated with the change in BP over time [42] [43] [44] . In these studies, changes in 25(OH)D over time, use of antihypertensive medications, measurement errors, or confounders may account for the null results.
In contrast, the results from interventional studies that have analyzed the effect of vitamin D supplementation on BP are mixed, with the majority of these analyses being small-scale trials not specifically designed to examine change in BP. A total of 13 randomized trials of vitamin D supplementation have reported results of change in BP comparing active supplementation with placebo [35•] . Many sources of heterogeneity may have contributed to the inconsistency in previous clinical trials, including small sample size; incomplete randomization; the lack of blinding in design; variable durations of follow-up; high rates of noncompliance; and differences in vitamin D treatment protocols, vitamin D formulation and dose, and study populations. In addition, BP assessment remains an important issue because BP is subject to a substantial degree of measurement error and can vary considerably in an individual from time to time. Most trials used clinic measurement and few trials used the 24-hour ambulatory BP. Secondary analysis of the largest randomized trial of calcium and vitamin D, the Women's Health Initiative (WHI) clinical trial, did not observe any effect from daily intake of 1,000 mg of elemental calcium plus 400 IU of vitamin D3 on BP and incident hypertension over 7 years of follow-up [45•] . However, the dose of vitamin D used in the WHI (400 IU/d) has been considered too low to raise serum 25(OH)D levels to the optimal levels for skeletal and nonskeletal health, particularly because the great majority of women in the WHI have been found to have baseline 25(OH)D less than 30 ng/mL [45•] . Additional research is needed to assess whether vitamin D with optimal dosage is beneficial for primary prevention of hypertension in the general population.
Type 2 Diabetes
To date, accumulating evidence in animal and laboratory studies indicates that vitamin D is essential for insulin secretion and action. Many clinical and epidemiologic studies have investigated the association of serum and dietary vitamin D with type 2 diabetes in humans. Earlier ecological studies have reported high prevalences of glucose intolerance and type 2 diabetes associated with vitamin D deficiency in some ethnic populations [46, 47] . Most relevant observational studies using dietary assessment information have focused on vitamin D-rich food groups such as dairy products and fish rather than specifically examining supplemental or total intake of vitamin D [48, 49] The largest randomized trial of vitamin D supplementation, the WHI clinical trial, evaluated vitamin D supplementation for the primary prevention of clinical diabetes in 33,951 initially nondiabetic postmenopausal women [51] . However, 400 IU/d of vitamin D raised median levels of serum 25(OH) D from 42.3 to only 54.1 nmol/L (~12 nmol/L), which is below the optimal value of 90 nmol/L or more for skeletal and nonskeletal health [52] . Clearly, direct evidence from future large-scale clinical trials of higher-dose vitamin D supplementation is warranted to clarify any beneficial effects of vitamin D supplementation on primary prevention of type 2 diabetes. Although randomized trials are critical for establishing cause-and-effect relationships between vitamin D and health outcomes, they will not be able to address all the unanswered questions based on their fixed dose (or at most a few doses) of vitamin D and narrow ranges of 25(OH)D levels in the study population. Prospective data have the ability to assess 25(OH)D thresholds and further our understanding of the physiology of vitamin D in relation to diabetes risk in the full spectrum of 25(OH)D levels.
Cardiovascular Disease
Effects of vitamin D on cardiometabolic risk factors, as reviewed above, would potentially lead to a change in the risk of CVD events. Several lines of epidemiologic evidence suggest a cardio-and cerebroprotective role for vitamin D. First, ecological studies show higher CVD mortality during the winter and in regions with less average exposure to UVB radiation from the sun [53] . Second, though not entirely consistent, results of cross-sectional, case-control, and cohort studies in healthy and ill populations suggest favorable associations in relation to vitamin D-as measured by circulating 25(OH)D, sun exposure, or dietary or supplement intake-on vascular risk factors, particularly hypertension [41, 54] ; impaired glucose tolerance, decreased insulin sensitivity, or type 2 diabetes [3, 55] ; and inflammation [33] . Low levels of circulating 25(OH)D have been found in patients with vascular calcification [56] , greater carotid intima-media thickness [57] , myocardial infarction [58] , stroke [59] , and other forms of vascular disease [60] . Third, prospective studies of healthy populations show that low bone density, often a result of vitamin D insufficiency, predicts increased risk of CVD [61, 62] . Prospective epidemiologic data on the association between vitamin D and clinical cardiovascular events are limited. Recent analyses from the Framingham Offspring Study suggest a significant relationship between low serum 25(OH)D and high risk of incident CVD (<37.5 vs ≥37.5 nmol/L; RR, 1.62 [95 % CI, 1.11-2.36]) [63] . In the Health Professionals Follow-Up Study, there was also a significant association between low serum 25(OH)D and high incident coronary heart disease risk (≤37.5 vs ≥75 nmol/L; RR, 2.09 [95 % CI, 1.24-3.54]) [64] . Overall, some, but not all, prospective studies found that lower 25(OH)D levels were associated with increased risk of incident CVD, including fatal cardiovascular events (cardiac or stroke), nonfatal stroke, and nonfatal myocardial infarction [65] . Some studies suggest a U-shaped relationship, with increased risk of CVD at both high and low 25 (OH)D levels. Obviously, the existing evidence is limited by the quality of the published studies. There was also substantial heterogeneity among studies, especially in vitamin D thresholds used, ethnic groups, outcomes specified, and confounders adjusted for. Moreover, most studies included only white participants, which limited the generalizability of the study findings to other racial groups. There are considerable variations in the rate of cardiovascular events and mortality between American non-Hispanic white and African American/black groups. The reasons for this disparity may relate to differential risk factor profiles of these two ethnic groups. Further research is needed to clarify whether differences in 25(OH)D and PTH levels by ethnicity might, at least in part, explain ethnic differences in CVD.
Indeed [66•] . The small number of studies, the lack of trials designed specifically to assess effects on cardiovascular outcomes, and large between-study heterogeneity preclude definitive conclusions. In the WHI CaD trial, the intervention of calcium (1,000 mg/d) plus low-dose vitamin D3 (400 IU/d) for 7 years did not reduce coronary heart disease or stroke incidence in 36,282 postmenopausal women [67] . Overall, these findings indicate that a protective effect of vitamin D supplementation on CVD is possible but that a large trial of vitamin D with an adequate dose is needed to assess its specific role in CVD prevention. Further randomized trials clearly will be important in establishing causality of the vitamin D-CVD relationship.
Ongoing Vitamin D Intervention Trial
Accumulating evidence from the new IOM guidelines suggests that vitamin D intake well above currently recommended amounts of 600 IU/d for adults aged 50 to 70 and 800 IU/d for adults older than 70 years of age is necessary for health benefits. Among postmenopausal women in the WHI, 400 IU/d of vitamin D3 raised median plasma 25(OH) D from 42.3 to only 54.1 nmol/L [51, 68] . In a review of studies of serum 25(OH)D in relation to multiple end points, including bone mineral density; lower extremity function; dental health; and risk of falls, fractures, and colorectal cancer, Bischoff-Ferrari et al. [69] found that for most end points, advantageous 25(OH)D levels began at 75 nmol/L, and optimal levels were 90 to 100 nmol/L. An average older adult requires an oral vitamin D3 intake of at least 800 to 1,000 IU/d (20-25 μg) to achieve a serum 25(OH)D of 75 nmol/L [52] . Extrapolation of these data suggests that it would require a dose of 2,000 IU/d (50 μg/d) to achieve a mean 25(OH)D level of about 80 to 90 nmol/L. The ongoing VITamin D and OmegA-3 TriaL (VITAL) is a large, randomized, double-blind, placebo-controlled, two-by-two factorial trial of vitamin D (in the form of vitamin D3
[cholecalciferol], 2,000 IU/d) and marine omega-3 fatty acid (eicosapentaenoic acid+docosahexaenoic acid, 1 g/d) supplements in the primary prevention of cancer and CVD in a multiethnic population of 20,000 US men 50 years of age and older and women 55 years of age and older [70••] . The vitamin D dose tested in the VITAL trial, 2,000 IU (50 μg)/ d, is well below the no-observed-adverse-effect level of 4,000 IU specified by the European Commission Scientific Committee on Food [71] . The mean treatment period of the VITAL trial will be 5 years. Yearly follow-up questionnaires will assess treatment compliance (plasma biomarker measures will also assess compliance in a random sample of participants), use of non-study drugs or supplements, occurrence of end points, and cancer and vascular risk factors. The primary aims of the trial are to test whether vitamin D3 or marine omega-3 fatty acid supplementation reduces the risk of total cancer and major CVD events (a composite end point of myocardial infarction, stroke, and cardiovascular mortality) [70••] . Ancillary studies will investigate whether these agents affect the risk of diabetes and glucose intolerance, hypertension, cognitive decline, depression, osteoporosis and fracture, physical disability and falls, asthma and other respiratory diseases, infections, and autoimmune disorders [ 
Conclusions
The link between vitamin D status and cardiometabolic disease is of great interest and potentially important for public health. There is growing evidence from experimental studies to indicate that vitamin D may influence risk of cardiometabolic disease through multiple pathways, including insulin secretion and action, adiposity, inflammation, lipids, RAS, and BP. However, the majority of studies on the association of vitamin D with cardiometabolic disease in humans have been observational in nature, hindering the ability to make further recommendations on vitamin D supplementation. Future well-designed randomized clinical trials are warranted to clarify the potential beneficial effect of vitamin D supplementation on preventing cardiometabolic disease, including hypertension, type 2 diabetes, and CVD.
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